Home | Welcome to Contract Pharma   
Last Updated Wednesday, May 27 2015


Financial Report: Gilead

Published July 26, 2013

2Q Revenues: $2.7 billion (+15%)

2Q Earnings: $767.6 million (+9%)

YTD Revenues: $5.1 billion (+12%)

YTD Earnings: $1.5 billion (+30%)

Comments: Antiviral product sales were up 15% to $2.3 billion in the quarter, driven by Viread, up 16% to $250.2 million, and Complera/Eviplera, up 159% to $188.7 million, along with Atripla sales, up 4% to $938.1 million, Truvada sales, up 3% to $807.8 million. Additionally, the company launched Stribild, which generated $99.4 million in sales. Cardiovascular product sales (Letairis and Ranexa) were $234.9 million in the quarter, up 19%. Royalty, contract and other revenues were $110.1 million, up 31%.

blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On